顿谤盲驳别谤 expands neonatal care portfolio with BiliPredics software solution
顿谤盲驳别谤 has expanded its neonatal care portfolio by introducing BiliPredics, a predictive software solution developed by NeoPredics for forecasting bilirubin progression in newborns. The innovative digital application can predict bilirubin levels up to 60 hours in advance, utilizing a database of over 50,000 bilirubin measurements from nearly 10,000 newborns.
The software aims to enhance jaundice management, which affects approximately 50% of all newborns and up to 80% of premature babies. BiliPredics integrates with electronic medical records and aligns with the 2022 AAP Hyperbilirubinemia Guideline, requiring minimal clinical parameters to generate insights.
The solution complements 顿谤盲驳别谤's existing jaundice management products, including the Jaundice Meter JM-105 for non-invasive measurements and the BiliLux Phototherapy Light for treatment. This comprehensive approach supports enhanced discharge planning and data-driven decision-making in neonatal care.
顿谤盲驳别谤 ha ampliato il suo portafoglio di cure neonatali introducendo BiliPredics, una soluzione software predittiva sviluppata da NeoPredics per prevedere la progressione della bilirubina nei neonati. Questa innovativa applicazione digitale pu貌 prevedere i livelli di bilirubina fino a 60 ore in anticipo, utilizzando un database di oltre 50.000 misurazioni di bilirubina provenienti da quasi 10.000 neonati.
Il software mira a migliorare la gestione dell'ittero, che colpisce circa il 50% di tutti i neonati e fino all'80% dei bambini prematuri. BiliPredics si integra con le cartelle cliniche elettroniche e si allinea con le linee guida AAP sulla iperbilirubinemia del 2022, richiedendo parametri clinici minimi per generare approfondimenti.
La soluzione completa i prodotti esistenti di gestione dell'ittero di 顿谤盲驳别谤, inclusi il Jaundice Meter JM-105 per misurazioni non invasive e la luce per fototerapia BiliLux per il trattamento. Questo approccio completo supporta una pianificazione delle dimissioni migliorata e decisioni basate sui dati nella cura neonatale.
顿谤盲驳别谤 ha ampliado su cartera de cuidados neonatales al introducir BiliPredics, una soluci贸n de software predictivo desarrollada por NeoPredics para pronosticar la progresi贸n de la bilirrubina en reci茅n nacidos. Esta innovadora aplicaci贸n digital puede predecir los niveles de bilirrubina hasta 60 horas antes, utilizando una base de datos de m谩s de 50,000 mediciones de bilirrubina de casi 10,000 reci茅n nacidos.
El software tiene como objetivo mejorar la gesti贸n de la ictericia, que afecta aproximadamente al 50% de todos los reci茅n nacidos y hasta al 80% de los beb茅s prematuros. BiliPredics se integra con los registros m茅dicos electr贸nicos y se alinea con la Gu铆a de Hiperbilirrubinemia de la AAP de 2022, requiriendo par谩metros cl铆nicos m铆nimos para generar informaci贸n.
La soluci贸n complementa los productos existentes de gesti贸n de ictericia de 顿谤盲驳别谤, incluidos el Jaundice Meter JM-105 para mediciones no invasivas y la luz de fototerapia BiliLux para el tratamiento. Este enfoque integral apoya una mejor planificaci贸n de altas y la toma de decisiones basada en datos en el cuidado neonatal.
顿谤盲驳别谤电� BiliPredics毳� 霃勳瀰頃橃棳 鞁犾儩鞎� 旃橂 韽姼韽措Μ鞓るゼ 頇曥灔頄堨姷雼堧嫟. 鞚吹鐢 NeoPredics鞐愳劀 臧滊皽頃� 鞓堨浮 靻岉攧韸胳洦鞏� 靻旊（靺橃溂搿�, 鞁犾儩鞎勳潣 牍岆Μ耄箞 歆勴枆 靸來櫓鞚� 鞓堨浮頃╇媹雼�. 鞚� 順侅嫚鞝侅澑 霐旍韯� 鞎犿攲毽紑鞚挫厴鞚� 瓯办潣 10,000氇呾潣 鞁犾儩鞎勲攵�韯� 靾橃霅� 50,000臧� 鞚挫儊鞚� 牍岆Μ耄箞 旄§爼臧掛潉 頇滌毄頃橃棳 斓滊寑 60鞁滉皠 鞝勳棎 牍岆Μ耄箞 靾橃箻毳� 鞓堨浮頃� 靾� 鞛堨姷雼堧嫟.
鞚� 靻岉攧韸胳洦鞏吹鐢 鞎� 50%鞚� 鞁犾儩鞎勳檧 斓滊寑 80%鞚� 臁办偘鞎勳棎瓴� 鞓來枼鞚� 氙胳箻电� 頇╇嫭 甏�毽ゼ 頄レ儊鞁滍偆电� 瓴冹潉 氇╉憸搿� 頃╇媹雼�. BiliPredics电� 鞝勳瀽 鞚橂 旮半瓿� 韱淀暕霅橂┌, 2022雲� AAP鞚� 瓿犽箤毽（牍堩槇歃� 臧�鞚措摐霛检澑瓿� 鞚检箻頃橂┌, 韱奠鞍霠レ潉 靸濎劚頃橁赴 鞙勴暣 斓滌唽頃滌潣 鞛勳儊 毵り皽氤�靾橂ゼ 鞖旉惮頃╇媹雼�.
鞚� 靻旊（靺橃潃 牍勳龚鞀奠爜 旄§爼鞚� 鞙勴暅 Jaundice Meter JM-105鞕� 旃橂毳� 鞙勴暅 BiliLux 甏戩箻耄岆摫鞚� 韽暔頃橃棳 顿谤盲驳别谤鞚� 旮办〈 頇╇嫭 甏�毽� 鞝滍拡鞚� 氤挫檮頃╇媹雼�. 鞚� 韽磩鞝侅澑 鞝戧芳 氚╈嫕鞚� 鞁犾儩鞎� 旃橂鞐愳劀 韲挫洂 瓿勴殟鞚� 臧滌劆頃橁碃 雿办澊韯� 旮半皹 鞚橃偓 瓴办爼鞚� 歆�鞗愴暕雼堧嫟.
顿谤盲驳别谤 a 茅largi son portefeuille de soins n茅onatals en introduisant BiliPredics, une solution logicielle pr茅dictive d茅velopp茅e par NeoPredics pour pr茅voir la progression de la bilirubine chez les nouveau-n茅s. Cette application num茅rique innovante peut pr茅dire les niveaux de bilirubine jusqu'脿 60 heures 脿 l'avance, en utilisant une base de donn茅es de plus de 50 000 mesures de bilirubine provenant de pr猫s de 10 000 nouveau-n茅s.
Le logiciel vise 脿 am茅liorer la gestion de la jaunisse, qui touche environ 50 % de tous les nouveau-n茅s et jusqu'脿 80 % des b茅b茅s pr茅matur茅s. BiliPredics s'int猫gre aux dossiers m茅dicaux 茅lectroniques et s'aligne sur les directives AAP de 2022 concernant l'hyperbilirubin茅mie, n茅cessitant des param猫tres cliniques minimaux pour g茅n茅rer des informations.
La solution compl猫te les produits existants de gestion de la jaunisse de 顿谤盲驳别谤, y compris le Jaundice Meter JM-105 pour des mesures non invasives et la lumi猫re de phototh茅rapie BiliLux pour le traitement. Cette approche globale soutient une meilleure planification des sorties et une prise de d茅cision bas茅e sur les donn茅es dans les soins n茅onatals.
顿谤盲驳别谤 hat sein Portfolio f眉r die neonatalen Pflege erweitert, indem es BiliPredics eingef眉hrt hat, eine pr盲diktive Softwarel枚sung, die von NeoPredics entwickelt wurde, um den Bilirubingehalt bei Neugeborenen vorherzusagen. Die innovative digitale Anwendung kann Bilirubinwerte bis zu 60 Stunden im Voraus vorhersagen und nutzt eine Datenbank mit 眉ber 50.000 Bilirubinmessungen von fast 10.000 Neugeborenen.
Die Software zielt darauf ab, das Management von Gelbsucht zu verbessern, das etwa 50 % aller Neugeborenen und bis zu 80 % der Fr眉hgeborenen betrifft. BiliPredics integriert sich in elektronische Patientenakten und entspricht den 2022 AAP-Richtlinien zur Hyperbilirubin盲mie, wobei nur minimale klinische Parameter erforderlich sind, um Erkenntnisse zu gewinnen.
Die L枚sung erg盲nzt die bestehenden Produkte von 顿谤盲驳别谤 zur Gelbsuchtbehandlung, einschlie脽lich des Jaundice Meter JM-105 f眉r nicht-invasive Messungen und des BiliLux Phototherapielichts zur Behandlung. Dieser umfassende Ansatz unterst眉tzt eine verbesserte Entlassungsplanung und datengest眉tzte Entscheidungsfindung in der neonatalen Pflege.
- Introduction of new revenue stream through BiliPredics software solution
- Large-scale validation with 50,000+ bilirubin measurements from 10,000 newborns
- Strategic partnership with NeoPredics strengthens market position
- Integration capabilities with existing hospital EMR systems
- None.
Innovative digital application predicts bilirubin, the biomarker for neonatal jaundice, helping to enhance early intervention and care
Key Benefits of BiliPredics:
- Enhanced Discharge Planning:聽Supports clinicians to help reduce unnecessary treatments, tests, and extended hospital stays through predictive insights into bilirubin progression.
- Data-Driven Decision Making:聽Utilizes an extensive database of over 50,000 individual bilirubin measurements of close to 10,000 newborns with a total of about 100,000 individual patient characteristics.聽
- Integrated Jaundice Management:聽Helps provide a streamlined pathway for screening, monitoring, and treating neonatal jaundice.
Advanced predictive capabilities
Neonatal jaundice affects approximately
Smooth integration with clinical workflows
BiliPredics requires only a few clinical parameters to generate comprehensive insights. It aligns with established guidelines, including the 2022 AAP Hyperbilirubinemia Guideline, and can integrate with electronic medical records (EMR) to display patient data within the dashboard. The system presents bilirubin trends through comprehensible curves, helping to allow for real-time assessment and intervention.
Strategic partnership to advance neonatal care
"Through our partnership with NeoPredics, we are expanding our offering with an innovative digital solution that strengthens our position as a leader in jaundice management," said Harald Kneuer, director of neonatal care at 顿谤盲驳别谤. "By combining 顿谤盲驳别谤's market expertise with NeoPredics' advanced predictive analytics, we are providing healthcare professionals with powerful tools to improve patient outcomes while managing costs."
NeoPredics CEO, Thorsten Waloschek, echoed this sentiment: "Our collaboration with 顿谤盲驳别谤 is a significant milestone in advancing neonatal care. Together, we are bridging innovative technology and clinical expertise to address critical challenges in jaundice management worldwide."
Comprehensive jaundice management solutions
顿谤盲驳别谤's neonatal care portfolio includes solutions for both screening and treatment of neonatal jaundice. The 顿谤盲驳别谤 Jaundice Meter JM-105 offers non-invasive, rapid bilirubin measurement, while the BiliLuxTM Phototherapy Light provides effective LED-based phototherapy for jaundice treatment. This approach helps ensure adherence to the latest guidelines, reinforcing the concept of "phototherapy as a drug" with precise irradiance dosing.
About 顿谤盲驳别谤
顿谤盲驳别谤 is a leading international medical and safety technology company. Our products protect, support and save lives. Founded in 1889, 顿谤盲驳别谤 generated global sales of around
NeoPredics
NeoPredics is a leader in predictive analytics and clinical decision support, with a focus on maternal and neonatal health. Committed to improving outcomes for women and children, NeoPredics develops state-of-the-art solutions like the FDA-registered and CE-certified Bilipredics jaundice management solution, addressing critical challenges in care with innovation and precision. For more information, visit聽
Note: The solution mentioned in this press release will not initially be available in all countries. For more information on the availability of products in your country, please visit the respective country website or contact the local 顿谤盲驳别谤 sales organization.
1Jardine LA, Woodgate P: Neonatal jaundice: phototherapy, ClinicalEvidence 2015;05:319, BMJ Publishing Group
Contact
Communications: Melanie Kamann, Tel. +49 451 882-3202, [email protected]
Press Contact North America: Laura Edwards, Tel. +1 215 565-5868, [email protected]
Investor Relations: Thomas Fischler, Tel. +49 451 882-2685, [email protected]
View original content to download multimedia:
SOURCE Draeger
FAQ
What is the prediction capability of 顿谤盲驳别谤's BiliPredics software for neonatal jaundice (DGWPF)?
How does BiliPredics software integrate with existing hospital systems (DGWPF)?
What percentage of newborns can benefit from 顿谤盲驳别谤's BiliPredics jaundice management system (DGWPF)?
What complementary products does 顿谤盲驳别谤 offer alongside BiliPredics for jaundice management (DGWPF)?
